Fig. 3From: Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot studyPFS and OS in patients with locally advanced ESCC. The PFS (a) and OS (b) adopting neoadjuvant camrelizumab plus chemotherapy in locally advanced ESCC. PFS, progression-free survival; OS, overall survival; ESCC, esophageal squamous cell carcinomaBack to article page